

## CORPORATE ACTION NOTICE

Amsterdam Market

No. CA160217DE

Issue Date:

17 February 2016

Effective Date:

18 February 2016

<b>Contracts:</b>	Single Stock Future (COB & <i>Flex</i> )	GO6, YGO
	Single Stock Dividend Future	GO8

**NOTE: This Notice replaces CA151113DE3**

**Company:** GlaxoSmithKline

**ISIN:** GB0009252882

**Corporate action:** Special dividend

**Reference:** Press release of 29 October 2015

**Details:** GlaxoSmithKline has announced payment of a special dividend of 20 pence per share and an ordinary dividend of 23 pence per share.

**Adjustments:** After the close of business on 17 February 2016 the following contract adjustments have been made:

- Ratio Method.
- Cum Event Price: Official closing price of GlaxoSmithKline shares on the London Stock Exchange on 17 February 2016.

$$\text{Ratio} = \frac{(\text{CumEventPrice} - 23\text{pence} - 20\text{pence})}{\text{CumEventPrice} - 23\text{pence}}$$

**Futures:**

- **Single Stock Dividend Futures:** Ordinary dividends with an ex-date on or before the Effective date will be multiplied by the Ratio, for the purpose of determining the EDSP at the end of the life time of the **Dec16** maturity in contract **GO8**.
- **Orders:** All outstanding orders for **GO6** and **GO8** will be cancelled automatically after the end of the trading session on 17 February 2016. The priority of these orders will then be lost. New orders in **GO6** and **GO8** can be submitted as from 18 February 2016.
- **Contract adjustments:** Given that there is no open interest, no other adjustments have been made to the contracts.

**CORPORATE ACTION NOTICE**

This Notice is issued pursuant to the Corporate Actions Policy for the Euronext Derivatives Markets which is available on the [Euronext website](#). It requires the immediate attention of Members’ staff involved with the trading and settlement of equity products on these markets. Members should ensure that clients are made aware of the arrangements detailed in this Notice.

For further information in relation to this Notice and/or the Corporate Action Services (“CAS”) provided by Euronext in respect to OTC Derivatives, Members should contact:

Euronext - <a href="#">EMS Corporate Actions</a>	+31 (0) 20 721 9588	Web: <a href="#">Corporate Actions</a>
Euronext - <a href="#">Corporate Action Services</a>	+31 (0) 20 721 9588	Web: <a href="#">CAS</a>
LCH.Clearnet SA - Derivatives Ops	+33 (0)1 7037 67 02	<a href="mailto:derivatives.ops.fr@lchclearnet.com">derivatives.ops.fr@lchclearnet.com</a>

The present notice and the contents thereof are only provided for information purposes in order to facilitate the fair, orderly and efficient functioning of the market and is not a recommendation to engage in investment activities. The contents of this notice are provided “as is” based on information provided to the market operator without representation or warranty of any kind. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this notice shall form the basis of any contract. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator.

The Euronext Markets comprise the markets operated by Euronext Amsterdam, Euronext Brussels, Euronext Lisbon, Euronext Paris and Euronext London, referred to respectively as the Amsterdam, Brussels, Lisbon, Paris and London markets, as relevant.

Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at <https://www.euronext.com/terms-use>.

© 2016 Euronext N.V. - All rights reserved.